2020-08-05
Maryland-based biotech Novavax announced it would receive $1.6bn in funding as part of the US government’s Covid-19 vaccine initiative “Operation Warp Speed” (OWS). The funding includes support for a Phase III clinical trial, for establishing large-scale manufacturing, and to deliver 100 million vaccine doses as early as late 2020.
